Neoadjuvant therapy has become increasingly plausible for patients with advanced pancreatic cancer, as the quantity and quality of approved therapies continue to increase, according to Colin Weekes, MD, PhD.
A potential biomarker to guide the treatment of patients with metastatic colorectal cancer (mCRC) failed to stratify patients by progression-free survival (PFS) or responsiveness to bevacizumab, according to a randomized trial.
Treatments can be better customized and tailored based on each patient's individual desires and characteristics, now that two effective options are available for refractory metastatic colorectal cancer, according to Jennifer Wu, MD.
The trial looked at radionuclide therapy Lu-Dotatate in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.
Marginal improvements were seen in clinical outcomes for patients with metastatic colorectal cancer (CRC) treated with FOLFOXIRI plus bevacizumab compared with FOLFOX plus bevacizumab; however, these findings were inconsistent, according to results from the phase II STEAM trial.